Interpretation of the 2024 American Diabetes Association guidelines for the comprehensive management of non-alcoholic fatty liver disease combined with diabetes mellitus
10.3760/cma.j.cn501113-20240119-00045
- VernacularTitle:非酒精性脂肪性肝病合并糖尿病的综合管理:2024年美国糖尿病学会指南解读
- Author:
Wenjing NI
1
;
Jie LI
;
Yuemin NAN
Author Information
1. 南京中医药大学鼓楼临床医学院感染性疾病科,南京 210008
- Keywords:
Non-alcoholic fatty liver disease;
Diabetes mellitus type 2;
Cardiometabolic risk factors;
Comprehensive management;
Diagnosis;
Treatment
- From:
Chinese Journal of Hepatology
2024;32(6):504-507
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a common concomitant disease in adults with type 2 diabetes mellitus (T2DM) and prediabetes. Therefore, T2DM/NAFLD patient populations are at high risk for cardiovascular disease. The occurrence and progression of non-alcoholic fatty liver disease-related liver fibrosis and cardiovascular disease have a severe impact on the patient’s prognosis and mortality rate. The American Diabetes Association's 2024 "Guidelines for the Standardized Management of Diabetes" put forward recommendations relevant to the screening, evaluation, treatment, and management of NAFLD in T2DM and prediabetic populations, as well as liver fibrosis. The important measures for decelerating liver inflammation and fibrosis progression and the risk of cardiovascular disease are based on improvements in lifestyle methods, weight loss, and blood sugar control.